Skip to content
TrialMatch
Sign up
Recruiting Phase 2

PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.

Create a profile to match View the full record on ClinicalTrials.gov

About this study

To look at the safety and effectiveness of stereotactic body radiation therapy (SBRT) in treating advanced or high-risk prostate cancer.

Condition
Advanced Prostate Cancer
Tested
Stereotactic Body Radiation Therapy
Sponsor
M.D. Anderson Cancer Center

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 11

  • Minimum age: 18 years
  • Study condition: Advanced Prostate Cancer
  • Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate within one year of study entry. Evaluation can happen outside of MD Anderson as long as histological confirmation takes place at MD Anderson.
  • cT1c-T3a by digital exam or imaging (AJCC 8th Ed.). No cT3b-4 by digital exam or imaging (AJCC 8th Ed.)
  • Gleason Grade Group 2-5 (Gleason 7, 8, 9, 10).
  • If Gleason Grade 2, must meet definition of unfavorable intermediate risk (at least one of the following: cT2b, and/or ≥ 50% biopsy cores positive, and/or PSA \>10 ng/mL prior to starting androgen deprivation therapy (ADT).
  • If a participant is taking 5-alpha reductase inhibitors the measured PSA may be doubled).
  • Node negative by conventional imaging.
  • Be ≥ 18 years of age on the day of signing informed consent.
  • Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both LHRH agonist and oral anti-androgen) is ≤ 185 days prior to registration; Please note: baseline PSA must be obtained prior to the start of any ADT.
  • ECOG performance status 0-2.

Exclusion 4

  • Diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe RT.
  • Prior prostatectomy, cryosurgery, or HIFU for adenocarcinoma of the prostate
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields
  • Distant metastatic disease on conventional imaging, which by the discretion of the treating physician cannot be treated definitively.

Where

1 site, 1 recruiting

MD Anderson Cancer Center

Houston, Texas, United States

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.